AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...
Cancer drugs are booming, obesity bets are rising, and a Trump deal just locked in three years of tariff-free growth.
Investor's Business Daily on MSN
AstraZeneca Bounds Into A Chase Zone As Cancer Drugs Drive Sales Beat
AstraZeneca stock bounded into a buy zone Thursday after sales of its cancer drugs beat Wall Street's expectations by about 5 ...
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...
In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (AZN) today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access ...
Eli Lilly and Novo Nordisk will lower prices for GLP-1 receptor agonists, aligning with the Most Favored Nation executive ...
Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...
Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...
Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback